首页> 外文期刊>npj Digital Medicine >Evaluation of a digitally-enabled care pathway for acute kidney injury management in hospital emergency admissions
【24h】

Evaluation of a digitally-enabled care pathway for acute kidney injury management in hospital emergency admissions

机译:在医院应急录取中对急性肾损伤管理进行数字化护理途径的评价

获取原文
           

摘要

We developed a digitally enabled care pathway for acute kidney injury (AKI) management incorporating a mobile detection application, specialist clinical response team and care protocol. Clinical outcome data were collected from adults with AKI on emergency admission before (May 2016 to January 2017) and after (May to September 2017) deployment at the intervention site and another not receiving the intervention. Changes in primary outcome (serum creatinine recovery to ≤120% baseline at hospital discharge) and secondary outcomes (30-day survival, renal replacement therapy, renal or intensive care unit (ICU) admission, worsening AKI stage and length of stay) were measured using interrupted time-series regression. Processes of care data (time to AKI recognition, time to treatment) were extracted from casenotes, and compared over two 9-month periods before and after implementation (January to September 2016 and 2017, respectively) using pre–post analysis. There was no step change in renal recovery or any of the secondary outcomes. Trends for creatinine recovery rates (estimated odds ratio (OR) = 1.04, 95% confidence interval (95% CI): 1.00–1.08, p = 0.038) and renal or ICU admission (OR = 0.95, 95% CI: 0.90–1.00, p = 0.044) improved significantly at the intervention site. However, difference-in-difference analyses between sites for creatinine recovery (estimated OR = 0.95, 95% CI: 0.90–1.00, p = 0.053) and renal or ICU admission (OR = 1.06, 95% CI: 0.98–1.16, p = 0.140) were not significant. Among process measures, time to AKI recognition and treatment of nephrotoxicity improved significantly (p  0.001 and 0.047 respectively).
机译:我们开发了一种数字化的护理途径,用于促进急性肾脏损伤(AKI)管理,该管理纳入移动检测应用,专业临床反应团队和护理方案。从成人收集临床结果数据,以急急入场(2016年5月至2017年1月)和2017年5月)和2017年9月)部署在干预现场之后,另一个没有收到干预。衡量了初级结果的变化(医院排放时≤120%基线)和二次结果(30天存活,肾脏替代治疗,肾脏或重症监护病房(ICU)入院,恶化的AKI阶段和逗留时间)使用中断的时间序列回归。从Casenotes中提取了护理数据(AKI识别时间,治疗时间),并在实施前后(分别为2016年1月至2016年至2017年度)之前和之后的两个9个月期间(分别为2016年9月,2016年9月)。肾脏恢复或任何二次结果没有步骤变化。肌酐素恢复率的趋势(估计的差距(或)= 1.04,95%置信区间(95%CI):1.00-1.08,P = 0.038)和肾或ICU入院(或= 0.95,95%CI:0.90-1.00 P = 0.044)在干预现场显着改善。但是,肌酐素恢复的部位之间的差异差异分析(估计或= 0.95,95%CI:0.90-1.00,P = 0.053)和肾或ICU入院(或= 1.06,95%CI:0.98-1.16,P = 0.140)不显着。在过程措施中,AKI识别和治疗肾毒性的时间显着改善(分别为P <0.001和0.047)。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号